SC
LXRX icon

Scotia Capital’s Lexicon Pharmaceuticals LXRX Stock Holding History

Scotia Capital’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117K Sell
48,871
-110,960
-69% -$216K ﹤0.01% 882
2026
Q1 		$249K Buy
+159,831
New +$232K ﹤0.01% 806

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Scotia Capital's LXRX Position: Q2 2026 in Review

Scotia Capital reduced its Lexicon Pharmaceuticals (LXRX) stake by 69% in Q2 2026, selling an estimated $216K and leaving 48,871 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #882.

Scotia Capital first reported a position in LXRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $249K in Q1 2026. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Scotia Capital held 48,871 shares of Lexicon Pharmaceuticals worth $117K as of Q2 2026.
  • Scotia Capital sold 110,960 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $216K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Scotia Capital's portfolio in Q2 2026, its #882 holding.
  • Scotia Capital first reported a position in Lexicon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Scotia Capital's Lexicon Pharmaceuticals position peaked at $249K in Q1 2026.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Scotia Capital's 13F filing for Q2 2026, filed 11 Aug 2026.